Ys Biopharma Co, Stock Current Ratio
YSDelisted Stock | 0.48 0.03 5.88% |
YS Biopharma Co, fundamentals help investors to digest information that contributes to YS Biopharma's financial success or failures. It also enables traders to predict the movement of YS Biopharma Stock. The fundamental analysis module provides a way to measure YS Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to YS Biopharma stock.
YS Biopharma |
YS Biopharma Co, Company Current Ratio Analysis
YS Biopharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, YS Biopharma Co, has a Current Ratio of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current ratio for all United States stocks is 100.0% higher than that of the company.
YS Biopharma Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses YS Biopharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of YS Biopharma could also be used in its relative valuation, which is a method of valuing YS Biopharma by comparing valuation metrics of similar companies.YS Biopharma is currently under evaluation in current ratio category among its peers.
YS Biopharma Fundamentals
Return On Equity | -0.78 | |||
Return On Asset | -0.1 | |||
Profit Margin | (0.67) % | |||
Operating Margin | (0.49) % | |||
Current Valuation | 429.47 M | |||
Shares Outstanding | 188.33 M | |||
Shares Owned By Insiders | 81.42 % | |||
Shares Owned By Institutions | 2.85 % | |||
Number Of Shares Shorted | 38.89 K | |||
Price To Book | 2.10 X | |||
Price To Sales | 0.29 X | |||
Revenue | 687.2 M | |||
EBITDA | (76.82 M) | |||
Net Income | (145.48 M) | |||
Total Debt | 498.63 M | |||
Book Value Per Share | 5.10 X | |||
Cash Flow From Operations | (182.47 M) | |||
Short Ratio | 0.31 X | |||
Earnings Per Share | (0.56) X | |||
Target Price | 4.17 | |||
Number Of Employees | 773 | |||
Beta | 0.54 | |||
Market Capitalization | 192.09 M | |||
Total Asset | 1.72 B | |||
Retained Earnings | (1.87 B) | |||
Working Capital | 377.22 M | |||
Net Asset | 1.72 B |
About YS Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze YS Biopharma Co,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma Co, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma Co, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |